Global Enzymatic DNA Synthesis Market Revenue Grows at a CAGR of 20.39%

Introduction

Straits Research released its highly anticipated report, “Global Enzymatic DNA Synthesis Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 353.04 million in 2025 and is projected to expand to USD 1,869.72 million by 2034, registering a compound annual growth rate (CAGR) of 20.39%.

Market Dynamics

The global enzymatic DNA synthesis market is gaining strong momentum, driven by the escalating demand for faster, more accurate, and environmentally sustainable DNA synthesis methods. A key market driver is the growing use of synthetic biology across therapeutics, diagnostics, gene editing, data storage, and industrial biotechnology. Traditional chemical DNA synthesis faces limitations in producing long, high-fidelity sequences and generates hazardous waste. In contrast, enzymatic approaches enable rapid, cleaner, and longer DNA assembly, making them highly attractive for newer applications such as personalized medicines, CRISPR-based therapies, and DNA-based data storage.

However, the market faces a major restraint in the form of high development costs and limited commercial maturity of enzymatic synthesis platforms. EDS technologies remain relatively new and require advanced enzymes, proprietary chemistries, and sophisticated instrumentation. This results in elevated pricing and slows widespread adoption, especially among smaller research labs and early-stage biotech firms. Despite this, the market holds substantial opportunities as advancements in gene therapies and cell engineering accelerate the need for longer, precise, and rapid DNA constructs. The shift toward automated benchtop “DNA printers,” along with partnerships between technology developers and biopharmaceutical companies, is expected to open significant growth avenues during the forecast period.

Market Highlights

• Service: The oligonucleotide synthesis segment dominated the market in 2025.
• Application: The vaccine development segment is estimated to grow at the fastest pace with a CAGR of 22.16%.
• End use: The biopharmaceutical companies segment dominated the market, accounting for 48.07% revenue share in 2025.
• Regional Insights: North America dominated the global market, accounting for 48.71% share in 2025. This growth is attributed to strong research and biotechnology infrastructure, coupled with heavy public and private investment in genomics and synthetic biology.

Competitive Players

1. Ansa Biotechnologies, Inc.
2. Bellatrix Aerospace
3. Camena Bioscience Ltd.
4. Codexis
5. DNA Script
6. Elegen Corporation
7. Eurofins Genomics
8. Evonetix
9. GenomeWeb
10. GenScript Biotech Corp.
11. Kern Systems, Inc.
12. Molecular Assemblies, Inc.
13. Moligo Technologies
14. Synbio Technologies
15. Telesis Bio Inc.
16. Touchlight Genetics Ltd.
17. Twist Bioscience Corporation
18. Yeasen Biotechnology
19. Others

Recent Developments

October 2025: Ansa Biotechnologies, a leading DNA synthesis company, launched the 50-kilobase (kb) Clonal DNA product, the longest sequence-perfect synthetic DNA commercially available.

Segmentation

1. By Service (2026-2034)
   1. Oligonucleotide Synthesis
   2. Gene Synthesis
2. By Application (2026-2034)
   1. Synthetic Biology
   2. Genetic Engineering
   3. Vaccine Development
   4. Others
3. By End Use (2026-2034)
   1. Biopharmaceutical Companies
   2. Academic & Research Institutes
   3. Contract Research Organizations